Data on the association of serum glypican-4 with future major adverse cardiovascular events and mortality in patients undergoing coronary angiography
Axel Muendlein,
Eva Maria Brandtner,
Andreas Leiherer,
Kathrin Geiger,
Christine Heinzle,
Stella Gaenger,
Peter Fraunberger,
Arthur Mader,
Christoph H. Saely,
Heinz Drexel
Affiliations
Axel Muendlein
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Corresponding author.
Eva Maria Brandtner
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria
Andreas Leiherer
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Medical Central Laboratories, Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein
Kathrin Geiger
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Medical Central Laboratories, Feldkirch, Austria
Christine Heinzle
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Medical Central Laboratories, Feldkirch, Austria
Stella Gaenger
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria
Peter Fraunberger
Medical Central Laboratories, Feldkirch, Austria
Arthur Mader
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Department of Internal Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
Christoph H. Saely
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Department of Internal Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
Heinz Drexel
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Department of Medicine and Cardiology, Academic Teaching Hospital Bregenz, Bregenz, Austria; Drexel University College of Medicine, Philadelphia, PA, USA
This data article is associated to the research article titled ‘Serum glypican-4 is a marker of future vascular risk and mortality in coronary angiography patients' (Muendlein et al., 2022). The present article provides additional prospective data on the association of serum glypican-4 (GPC4) with the incidence of future major adverse cardiovascular events (MACE), vascular mortality, and overall mortality in a cohort of 760 coronary angiography patients.Serum GPC4 levels significantly differed between patients with or without an event during follow up. The results were confirmed in subgroup analyses with respect to age, sex, type 2 diabetes mellitus, obesity, the presence of significant coronary stenoses, and renal function, as well as medical treatment. That said, an interaction term between GPC4 and impaired renal function and between GPC4 and the use of beta blockers on the incidence of future fatal events reached statistical significance. In addition, C-statistics were performed showing an additional predictive value of categorized GPC4 to a basic risk model including traditional risk factors for overall mortality.
